Evidence map›Paper›PMID 36828335›Full record

ArticleThe Journal of infection2023

Enriched CXCR3

Pengcheng Zhou, Fang Gong, Tuo Ji, Cheng Cao, Ting Zheng

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. An angel or a devil? Current view on the role of CD8Journal of translational medicine · 2024
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pengcheng ZhouDepartment of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China; The University of Queensland Diamantina Institute, Brisbane, Australia. Electronic address: whuzpc@hotmail.com.
Fang GongDepartment of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.
Tuo JiDepartment of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China; Department of Central Laboratory, The Second People's Hospital of Lianyungang City (Cancer Hospital of Lianyungang), Lianyungang, Jiangsu, China.
Cheng CaoDepartment of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China; Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Ting ZhengQilu University of Technology (Shandong Academy of Sciences), Shandong Analysis and Test Center, Laboratory of Immunology for Environment and Health, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD8-Positive T-LymphocytesCOVID-19CD4-Positive T-LymphocytesHumansReceptors, CXCR3Receptors, CXCR5SARS-CoV-2CXCR3 protein, humanCXCR5 protein, humanReceptors, CXCR3Receptors, CXCR5

Identifiers

PMID36828335
PMCPMC9946775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.